David Hager
Internal Medicine · Denver, CONPI 1790858579
Payments from drug & device makers
Across 389 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$929
- AbbVie$673
- Boehringer Ingelheim$592
- Johnson & Johnson$518
- Lilly USA, LLC$499
- GSK$418
- plus $3K from 39 others
What the payments were for
- Food & beverage$6,935100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$6,947 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 105 | $121,700 |
| JardianceEmpagliflozin | 45 | $63,370 |
| EliquisApixaban | 64 | $59,169 |
| XareltoRivaroxaban | 52 | $51,430 |
| MounjaroTirzepatide | 36 | $44,574 |
| RybelsusSemaglutide | 13 | $37,023 |
| OzempicSemaglutide | 15 | $21,507 |
| JanuviaSitagliptin Phosphate | 12 | $16,560 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $11,957 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,800 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $3,468 |
| Telmisartan | 179 | $3,409 |
| Atorvastatin Calcium | 343 | $2,764 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $2,456 |
| Amlodipine Besylate | 335 | $2,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $499 | $166,274141 claims |
| Boehringer IngelheimJardiance | $592 | $63,37045 claims |
| PfizerEliquis | $277 | $59,16964 claims |
| Novo NordiskRybelsus, Ozempic | $929 | $58,53128 claims |
| Johnson & JohnsonXarelto | $518 | $51,43052 claims |
| MerckJanuvia | $116 | $16,56012 claims |
| GSKTrelegy Ellipta | $418 | $11,95716 claims |
| AstraZenecaSymbicort | $399 | $4,80014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Denver
- Jason HenryDenver$7.3M
- Thomas StarkeyDenver$391K
- Matthew KoslowDenver$182K
- Keith HruskaDenver$167K
- Kenneth OleszekDenver$60K
- Robert KeithDenver$49K
- Elena AnisimovaDenver$36K
- Chase BlackfordDenver$30K
- Samuel BrownDenver$18K
- Katherine TsaiDenver$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.